Thromboxane mediates the renal hemodynamic effects of platelet activating factor

J. Yoo, D. Schlondorff, Joel Neugarten

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The mechanism by which platelet-activating factor affects renal hemodynamics is controversial. In the present study we examined the hypothesis that thromboxane mediates the renal hemodynamic response to platelet activating factor (PAF) by determining the effects of pretreatment with a selective thromboxane receptor antagonist. Infusion of platelet-activating factor into the left renal artery of normal rats in a dose that failed to alter mean arterial pressure or blood hematocrit values reduced urinary flow rate from 25.9 ± 6.3 to 12.6 ± 1.5 μl/min (P < .01), reduced effective renal plasma flow rate from 14.01 ± 2.09 to 5.42 ± 2.38 ml/min/kg body weight (P < .01), reduced glomerular filtration rate from 4.81 ± 1.00 to 1.68 ± 0.34 ml/min/kg (P < .03), and increased the fractional excretion of protein from 0.021 ± 0.008 to 0.094 ± 0.005 percent (P < .05). Pretreatment with the selective thromboxane receptor antagonist SKF 96148 (10 mg/kg) not only prevented PAF-induced reductions in effective renal plasma flow rate and glomerular filtration rate but increased these values (effective renal plasma flow rate: 14.09 ± 2.76 vs. 16.84 ± 2.08 ml/min/kg, P < .05; glomerular filtration rate: 4.42 ± 0.43 vs. 5.50 ± 0.59 ml/min/kg, P < .03) and aborted proteinuria. Pretreatment with indomethacin (2 mg/kg) ameliorated PAF-induced alterations in renal hemodynamics and glomerular permselectivity in the final collection period. Infusion of lyso-PAF, a biologically inactive precursor of PAF, or of indomethacin alone or SKF 96148 alone had no significant effect on measured parameters. These observations suggest that thromboxane mediates the renal hemodynamic and permselective effects of PAF.

Original languageEnglish (US)
Pages (from-to)743-748
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume253
Issue number2
StatePublished - 1990

Fingerprint

Platelet Activating Factor
Thromboxanes
Hemodynamics
Kidney
Effective Renal Plasma Flow
Glomerular Filtration Rate
Thromboxane Receptors
Indomethacin
Renal Artery
Hematocrit
Proteinuria
Arterial Pressure
Body Weight
Proteins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Thromboxane mediates the renal hemodynamic effects of platelet activating factor. / Yoo, J.; Schlondorff, D.; Neugarten, Joel.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 253, No. 2, 1990, p. 743-748.

Research output: Contribution to journalArticle

@article{dfca32d4be794f2f942bed1483f0bfe3,
title = "Thromboxane mediates the renal hemodynamic effects of platelet activating factor",
abstract = "The mechanism by which platelet-activating factor affects renal hemodynamics is controversial. In the present study we examined the hypothesis that thromboxane mediates the renal hemodynamic response to platelet activating factor (PAF) by determining the effects of pretreatment with a selective thromboxane receptor antagonist. Infusion of platelet-activating factor into the left renal artery of normal rats in a dose that failed to alter mean arterial pressure or blood hematocrit values reduced urinary flow rate from 25.9 ± 6.3 to 12.6 ± 1.5 μl/min (P < .01), reduced effective renal plasma flow rate from 14.01 ± 2.09 to 5.42 ± 2.38 ml/min/kg body weight (P < .01), reduced glomerular filtration rate from 4.81 ± 1.00 to 1.68 ± 0.34 ml/min/kg (P < .03), and increased the fractional excretion of protein from 0.021 ± 0.008 to 0.094 ± 0.005 percent (P < .05). Pretreatment with the selective thromboxane receptor antagonist SKF 96148 (10 mg/kg) not only prevented PAF-induced reductions in effective renal plasma flow rate and glomerular filtration rate but increased these values (effective renal plasma flow rate: 14.09 ± 2.76 vs. 16.84 ± 2.08 ml/min/kg, P < .05; glomerular filtration rate: 4.42 ± 0.43 vs. 5.50 ± 0.59 ml/min/kg, P < .03) and aborted proteinuria. Pretreatment with indomethacin (2 mg/kg) ameliorated PAF-induced alterations in renal hemodynamics and glomerular permselectivity in the final collection period. Infusion of lyso-PAF, a biologically inactive precursor of PAF, or of indomethacin alone or SKF 96148 alone had no significant effect on measured parameters. These observations suggest that thromboxane mediates the renal hemodynamic and permselective effects of PAF.",
author = "J. Yoo and D. Schlondorff and Joel Neugarten",
year = "1990",
language = "English (US)",
volume = "253",
pages = "743--748",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Thromboxane mediates the renal hemodynamic effects of platelet activating factor

AU - Yoo, J.

AU - Schlondorff, D.

AU - Neugarten, Joel

PY - 1990

Y1 - 1990

N2 - The mechanism by which platelet-activating factor affects renal hemodynamics is controversial. In the present study we examined the hypothesis that thromboxane mediates the renal hemodynamic response to platelet activating factor (PAF) by determining the effects of pretreatment with a selective thromboxane receptor antagonist. Infusion of platelet-activating factor into the left renal artery of normal rats in a dose that failed to alter mean arterial pressure or blood hematocrit values reduced urinary flow rate from 25.9 ± 6.3 to 12.6 ± 1.5 μl/min (P < .01), reduced effective renal plasma flow rate from 14.01 ± 2.09 to 5.42 ± 2.38 ml/min/kg body weight (P < .01), reduced glomerular filtration rate from 4.81 ± 1.00 to 1.68 ± 0.34 ml/min/kg (P < .03), and increased the fractional excretion of protein from 0.021 ± 0.008 to 0.094 ± 0.005 percent (P < .05). Pretreatment with the selective thromboxane receptor antagonist SKF 96148 (10 mg/kg) not only prevented PAF-induced reductions in effective renal plasma flow rate and glomerular filtration rate but increased these values (effective renal plasma flow rate: 14.09 ± 2.76 vs. 16.84 ± 2.08 ml/min/kg, P < .05; glomerular filtration rate: 4.42 ± 0.43 vs. 5.50 ± 0.59 ml/min/kg, P < .03) and aborted proteinuria. Pretreatment with indomethacin (2 mg/kg) ameliorated PAF-induced alterations in renal hemodynamics and glomerular permselectivity in the final collection period. Infusion of lyso-PAF, a biologically inactive precursor of PAF, or of indomethacin alone or SKF 96148 alone had no significant effect on measured parameters. These observations suggest that thromboxane mediates the renal hemodynamic and permselective effects of PAF.

AB - The mechanism by which platelet-activating factor affects renal hemodynamics is controversial. In the present study we examined the hypothesis that thromboxane mediates the renal hemodynamic response to platelet activating factor (PAF) by determining the effects of pretreatment with a selective thromboxane receptor antagonist. Infusion of platelet-activating factor into the left renal artery of normal rats in a dose that failed to alter mean arterial pressure or blood hematocrit values reduced urinary flow rate from 25.9 ± 6.3 to 12.6 ± 1.5 μl/min (P < .01), reduced effective renal plasma flow rate from 14.01 ± 2.09 to 5.42 ± 2.38 ml/min/kg body weight (P < .01), reduced glomerular filtration rate from 4.81 ± 1.00 to 1.68 ± 0.34 ml/min/kg (P < .03), and increased the fractional excretion of protein from 0.021 ± 0.008 to 0.094 ± 0.005 percent (P < .05). Pretreatment with the selective thromboxane receptor antagonist SKF 96148 (10 mg/kg) not only prevented PAF-induced reductions in effective renal plasma flow rate and glomerular filtration rate but increased these values (effective renal plasma flow rate: 14.09 ± 2.76 vs. 16.84 ± 2.08 ml/min/kg, P < .05; glomerular filtration rate: 4.42 ± 0.43 vs. 5.50 ± 0.59 ml/min/kg, P < .03) and aborted proteinuria. Pretreatment with indomethacin (2 mg/kg) ameliorated PAF-induced alterations in renal hemodynamics and glomerular permselectivity in the final collection period. Infusion of lyso-PAF, a biologically inactive precursor of PAF, or of indomethacin alone or SKF 96148 alone had no significant effect on measured parameters. These observations suggest that thromboxane mediates the renal hemodynamic and permselective effects of PAF.

UR - http://www.scopus.com/inward/record.url?scp=0025298825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025298825&partnerID=8YFLogxK

M3 - Article

C2 - 2140130

AN - SCOPUS:0025298825

VL - 253

SP - 743

EP - 748

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -